Skip to main content
C.Q. Pharmaceutical Holding Co., Ltd. logo

C.Q. Pharmaceutical Holding Co., Ltd. — Investor Relations & Filings

Ticker · 000950 ISIN · CNE0000010K0 Shenzhen Stock Exchange Wholesale and retail trade
Open in API
Filings indexed 2,883 across all filing types
Latest filing 2024-12-20 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 000950

About C.Q. Pharmaceutical Holding Co., Ltd.

https://www.cqphar.com

C.Q. Pharmaceutical Holding Co., Ltd. is a comprehensive pharmaceutical enterprise specializing in the distribution, retail, and supply chain management of healthcare products. The company operates an extensive network focused on the wholesale of pharmaceuticals and medical devices, providing integrated logistics and warehousing solutions to healthcare providers and manufacturers. Its core business activities encompass the procurement and distribution of a wide range of prescription drugs, over-the-counter medications, and specialized medical equipment. Through its retail pharmacy operations and third-party logistics services, the company facilitates the efficient delivery of medical supplies. C.Q. Pharmaceutical Holding Co., Ltd. emphasizes technological integration within its supply chain to optimize inventory management and ensure the integrity of healthcare products throughout the distribution lifecycle.

Recent filings

Filing Released Lang Actions
第八届监事会第三十一次会议决议公告
Board/Management Information Classification · 95% confidence The document is a resolution announcement from the Supervisory Board (监事会) of the company, detailing the meeting date, attendance, and voting results on specific agenda items such as renaming a committee and related work rules, and daily related-party transactions. It does not contain financial statements or detailed financial data. It is a formal announcement of board/committee decisions rather than a full management report or financial report. This fits best under Board/Management Information (MANG), which covers announcements of changes or decisions by company boards or senior management bodies. The document length is short and focused on meeting resolutions, not a full report or regulatory filing. Therefore, the classification is MANG with high confidence.
2024-12-20 Chinese
重药控股股份有限公司收购报告书
M&A Activity Classification · 100% confidence The document is titled "重药控股股份有限公司收购报告书" which translates to "Acquisition Report of Chongqing Pharmaceutical Holdings Co., Ltd." It contains detailed information about the acquisition, including the acquirer's identity, shareholding changes, legal and regulatory references, financial data of the acquirer, and the acquisition process. The document references specific laws and regulations related to acquisitions, such as the "上市公司收购管理办法" (Measures for the Administration of Takeovers of Listed Companies). It also includes detailed sections on the acquisition decision, purpose, method, and related agreements. This is a comprehensive acquisition report, not merely an announcement or a proxy statement. Therefore, the document fits the category of M&A Activity (Code: TAR), which covers announcements and documents related to merger proposals or takeover bids.
2024-12-20 Chinese
关于控股股东国有股权无偿划转免于发出要约的提示性公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement regarding a change in the company's controlling shareholder due to a state-owned equity transfer without consideration. It references compliance with the "Measures for the Administration of the Takeover of Listed Companies" and states that the transaction is exempt from making a takeover offer. The document includes dates of previous related announcements and approvals from regulatory bodies. The text is relatively short (1691 characters) and primarily serves as a notification of the equity transfer and the resulting change in actual controller. It does not contain financial statements, detailed financial analysis, or comprehensive report content. It is not a full report but an announcement about a corporate action related to ownership change and exemption from a takeover offer. Therefore, it fits best under the category of Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes, including changes in control and equity transfers.
2024-12-20 Chinese
关于召开2025年第一次临时股东会的通知
AGM Information Classification · 95% confidence The document is a notice about convening the 2025 first extraordinary general meeting (临时股东会) of the company 重药控股股份有限公司. It details the meeting date, voting procedures, registration, and agenda items, including related party transactions. It does not contain financial statements or results but is an announcement about the meeting itself. The document length is 4175 characters, which is relatively short and consistent with a meeting notice rather than a full report. Therefore, this document fits the category of AGM Information (AGM-R), which covers presentations and materials shared during the Annual General Meeting or similar shareholder meetings.
2024-12-20 Chinese
关于实际控制人拟发生变更事项的进展公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the progress of a change in the actual controlling shareholder of the company. It details previous announcements, regulatory approvals, and the status of share transfers related to the controlling shareholder. There is no financial data, no report attached or referenced as being published, and no indication of a full report or detailed financial statements. The document is a regulatory announcement about ownership/control changes, which fits best under Regulatory Filings (RNS) as it does not fit other more specific categories like Major Shareholding Notification (MRQ) because it discusses control changes and approvals rather than threshold shareholding changes. The document length is short and it is an announcement, not a report itself.
2024-12-18 Chinese
关于控股子公司2024年度第五期中期票据发行结果公告
Capital/Financing Update Classification · 100% confidence The document is an announcement regarding the issuance results of the fifth tranche of medium-term notes (MTN) by a controlling subsidiary of the company. It details the registration, issuance date, amount raised, interest rate, and underwriters. The document is short (1474 characters) and focuses on the financing activity, specifically the issuance of debt securities. It does not contain financial statements or detailed financial analysis but rather provides an update on capital raising activities. Therefore, it fits the category of Capital/Financing Update (CAP).
2024-12-13 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.